Atrium Therapeutics, Inc. (RNA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 19.64M | 859K | 12.47M | 3.85M | 1.57M | 2.97M | 2.34M | 2.04M | 3.54M | 2.19M | 2.82M | 2.32M |
| Revenue Growth % | 1148.25% | -71.11% | 434.03% | 88.12% | -55.6% | 35.57% | -17.1% | -11.7% | 58.67% | -20.8% | 13.54% | 6.34% |
| Cost of Goods Sold | 151K | 0 | 0 | 138.13M | 0 | 0 | 0 | 687K | 641K | 615K | 47.71M | 42.67M |
| COGS % of Revenue | 0.77% | - | - | 3590.46% | - | - | - | 33.59% | 18.09% | 28.04% | 1693.19% | 1842.49% |
| Gross Profit | 19.48M | 859K | 12.47M | -134.28M | 1.57M | 2.97M | 2.34M | 1.36M | 2.9M | 1.58M | -44.9M | -40.36M |
| Gross Margin % | 99.23% | 100% | 100% | -3490.46% | 100% | 100% | 100% | 66.41% | 81.91% | 71.96% | -1593.19% | -1742.49% |
| Gross Profit Growth % | 1138.65% | -71.11% | 434.03% | -9987.92% | -45.8% | 88.4% | 105.2% | 103.37% | 106.37% | 103.68% | -28.88% | -7.3% |
| Operating Expenses | 36.76M | 48.89M | 201.28M | 36.86M | 133.09M | 123.96M | 100.47M | 83.98M | 80.09M | 68.32M | 13.73M | 12.28M |
| OpEx % of Revenue | 187.24% | 5691.97% | 1613.47% | 958.25% | 8460.9% | 4169.63% | 4300.94% | 4106.8% | 2260.49% | 3115.41% | 487.19% | 530.14% |
| Selling, General & Admin | 20.11M | 30.4M | 46.33M | 36.86M | 33.6M | 28.34M | 23.27M | 20.73M | 13.26M | 15.5M | 13.73M | 12.28M |
| SG&A % of Revenue | 102.4% | 3538.65% | 371.41% | 958.25% | 2136.05% | 953.18% | 996.28% | 1013.74% | 374.17% | 706.98% | 487.19% | 530.14% |
| Research & Development | 16.66M | 18.5M | 154.95M | 138.13M | 99.49M | 95.63M | 77.2M | 63.94M | 66.83M | 52.82M | 47.71M | 42.67M |
| R&D % of Revenue | 84.83% | 2153.32% | 1242.07% | 3590.46% | 6324.86% | 3216.45% | 3304.67% | 3126.65% | 1886.31% | 2408.44% | 1693.19% | 1842.49% |
| Other Operating Expenses | 0 | 0 | 0 | -1000K | 0 | 0 | 0 | -687K | 0 | 0 | -1000K | -1000K |
| Operating Income | -17.28M | -48.03M | -188.81M | -171.14M | -131.52M | -120.99M | -98.13M | -82.63M | -77.19M | -66.74M | -58.63M | -52.63M |
| Operating Margin % | -88.01% | -5591.97% | -1513.47% | -4448.71% | -8360.9% | -4069.63% | -4200.94% | -4040.39% | -2178.58% | -3043.46% | -2080.38% | -2272.63% |
| Operating Income Growth % | 86.86% | 60.3% | -92.4% | -107.13% | -70.39% | -81.28% | -67.39% | -56.98% | -34.01% | -25.4% | -30.48% | -13.68% |
| EBITDA | -17.13M | -47.91M | -187.75M | -170.33M | -130.73M | -120.25M | -97.42M | -81.94M | -76.55M | -66.13M | -58.06M | -52.1M |
| EBITDA Margin % | -87.24% | -5577.76% | -1505.01% | -4427.55% | -8311% | -4044.8% | -4170.55% | -4006.8% | -2160.49% | -3015.41% | -2060.29% | -2249.78% |
| EBITDA Growth % | 86.9% | 60.16% | -92.71% | -107.87% | -70.79% | -81.85% | -67.8% | -57.26% | -33.81% | -25.14% | -30.3% | -13.33% |
| D&A (Non-Cash Add-back) | 151K | 122K | 1.06M | 814K | 785K | 738K | 710K | 687K | 641K | 615K | 566K | 529K |
| EBIT | -17.28M | -48.03M | -174.44M | -171.14M | -131.52M | -120.99M | -98.13M | -82.63M | -77.19M | -66.74M | -58.63M | -52.63M |
| Net Interest Income | 0 | 0 | 14.74M | 14.48M | 16.18M | 18.53M | 17.97M | 11.95M | 8.43M | 6.41M | 6.28M | 5.77M |
| Interest Income | 0 | 0 | 14.74M | 14.48M | 16.18M | 18.53M | 17.97M | 11.95M | 8.43M | 6.41M | 6.28M | 5.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 647K | 0 | 14.36M | 13.83M | 15.74M | 18.73M | 17.74M | 11.83M | 8.33M | 6.3M | 6.27M | 5.61M |
| Pretax Income | -16.63M | -48.03M | -174.44M | -157.31M | -115.77M | -102.26M | -80.4M | -70.79M | -68.86M | -60.44M | -52.36M | -47.02M |
| Pretax Margin % | -84.71% | -5591.97% | -1398.33% | -4089.29% | -7360.01% | -3439.52% | -3441.7% | -3461.76% | -1943.41% | -2756.18% | -1857.98% | -2030.44% |
| Income Tax | 0 | 34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.07% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -16.63M | -48.07M | -174.44M | -157.31M | -115.77M | -102.26M | -80.4M | -70.79M | -68.86M | -60.44M | -52.36M | -47.02M |
| Net Margin % | -84.71% | -5595.93% | -1398.33% | -4089.29% | -7360.01% | -3439.52% | -3441.7% | -3461.76% | -1943.41% | -2756.18% | -1857.98% | -2030.44% |
| Net Income Growth % | 85.63% | 52.99% | -116.97% | -122.22% | -68.14% | -69.18% | -53.55% | -50.54% | -31.42% | -19.76% | -20.09% | -2.92% |
| Net Income (Continuing) | -16.63M | -48.07M | -174.44M | -157.31M | -115.77M | -102.26M | -80.4M | -70.79M | -68.86M | -60.44M | -52.36M | -47.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.97 | -1.70 | -1.27 | -1.21 | -0.90 | -0.80 | -0.65 | -0.66 | -0.79 | -0.79 | -0.71 | -0.66 |
| EPS Growth % | -7.78% | -112.5% | -95.38% | -83.33% | -13.92% | -1.27% | 8.45% | 0% | -17.91% | 4.82% | 11.25% | 28.26% |
| EPS (Basic) | -0.97 | -1.70 | -1.27 | -1.21 | -0.90 | -0.80 | -0.65 | -0.66 | -0.79 | -0.79 | -0.71 | -0.66 |
| Diluted Shares Outstanding | 17.11M | 17.11M | 137.9M | 129.62M | 129.23M | 128.5M | 123.38M | 106.93M | 87.21M | 76.05M | 74.1M | 71.39M |
| Basic Shares Outstanding | 17.11M | 17.11M | 137.9M | 129.62M | 129.23M | 128.5M | 123.38M | 106.93M | 87.21M | 76.05M | 74.1M | 71.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |